Hurley Capital
AQST icon

Hurley Capital’s Aquestive Therapeutics AQST Stock Holding History

Hurley Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.26K Hold
1,569
– – ﹤0.01% 365
2026
Q2 		$6.53K Buy
+1,569
New +$6.6K ﹤0.01% 381
2026
Q1 		– Sell
-1,569
Closed -$10.1K – 679
2025
Q4 		$10.1K Hold
1,569
– – 0.01% 330
2025
Q3 		$8.77K Hold
1,569
– – ﹤0.01% 378
2025
Q2 		$5.19K Hold
1,569
– – ﹤0.01% 366
2025
Q1 		$4.55K Hold
1,569
– – ﹤0.01% 383
2024
Q4 		$5.62K Buy
+1,569
New +$7.24K ﹤0.01% 323

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Hurley Capital's AQST Position: Q3 2026 in Review

Hurley Capital held its Aquestive Therapeutics (AQST) position steady in Q3 2026 at 1,569 shares worth $7.26K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Hurley Capital first reported a position in AQST in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.1K in Q4 2025. 87 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Hurley Capital held 1,569 shares of Aquestive Therapeutics worth $7.26K as of Q3 2026.
  • Hurley Capital left its Aquestive Therapeutics share count unchanged in Q3 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #365 holding.
  • Hurley Capital first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Hurley Capital's Aquestive Therapeutics position peaked at $10.1K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.